Company Profile

Top Page > Company Profile TOP

Company Profile TOP

>> Company Overview

Find out basic facts about MBL.

>> Lines of Business


Corporate Mission

We, MBL, are offering novel diagnostic reagents to meet
healthcare needs of patients, no matter many or few.

MBL’s Vision for the Future

A global niche company with a strong presence,
we are creating values at the cutting-edge of diagnostics.

Message from the President

The life sciences industry is providing innovative therapeutic approaches and diagnostic tools, such as break-through immunotherapeutic agents, genome diagnostics, AI diagnostic devices and digital healthcare, for use in clinical practice throughout the world. In Japan too, highly needed therapeutic and diagnostic methods in the area of precision medicine are coming into practical use through, for example, improved ecacy in cancer immunotherapy with iPS cells and new technological advances in vaccine therapies. MBL, as a member of a corporate group responsible for developing cutting-edge diagnostic products, believes that its corporate mission is to contribute to the improvement of medical-care quality and saving of medical expenses.

MBL began its history in 1969 as the first Japanese company specializing in the production and supply of antibodies and has broadened its basis of operations from immunology to molecular biology and then epigenetics. While maintaining close research and development relationships with academic institutes and pharmaceutical companies, we also provide clinical diagnostics and research reagents for protein and genetic analysis primarily for autoimmune diseases, cancers, gynecologic diseases and infectious diseases. In recent years, MBL has also focused its product development on biomarkers, companion diagnostics and reagents for regenerative medicine by utilizing its expertise in immune and gene-detection technologies.

We understand that MBL’s clinical diagnostics play a critical role in helping practitioners to not only diagnose diseases but also predict disease progression and decide on treatment options for individual patients. MBL will contribute to advancing the optimization of medical treatment under our philosophy, “the most suitable treatment at the most suitable time for every patient,” through the development and supply of clinical diagnostics pivotal for the selection of the best course of treatment. To fulfill this commitment, we will further endeavor to improve our quality management systems for diagnostic products throughout all our processes from research and development to regulatory approval, manufacturing, marketing, distribution and technical support.

From the perspectives of product innovation and expanding market size in the life science industry, it is impossible to overlook the increasing importance of the People’s Republic of China and the United States, which dominate the markets in other countries and regions. As a consolidated subsidiary of JSR Corporation, MBL has integrated its life sciences business with JSR Corporation. We are now actively collaborating with JSR in research and development activities and extending our global business operations in the United States, Europe and China.

It is our desire to contribute to society as “a globally-recognized niche company capable of creating value in the field of cutting-edge diagnostics” under our corporate vision within the ever diversifying and profoundly changing life science industry. It is my sincere hope that you will grant us your continued support and guidance.


October 2018

President and CEO
Kimimasa Yamada

Full Site